Don't give Delphion your money for no reason, go to USPTO:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1
&u=/netahtml/srchnum.htm&r=1&f=G&l=50&s1='6034073'.WKU.&OS=PN/6034073&RS=PN/
6034073
The patent no. is 6034073
I have grabbed the recipe details (part of patent) so there is no need to go
there at all...
=======================================================
Example 1
In this Example, several virus-inactivating oil-in-water emulsions, each
including a surfactant and a trialkyl phosphate, were formed and
characterized.
The emulsions were formed as follows: an oil phase was made by blending
tributyl phosphate, soybean oil, and a surfactant (either Triton X- 100,
Tween 20 or Tween 80) and then heating the resulting mixture at 86.degree.
C. for one hour. An emulsion was then produced by injecting water into the
oil phase at a volume/volume ratio of one part oil phase to four parts
water. The emulsions were produced manually, with reciprocating syringe
instrumentation, or with continuous flow instrumentation. Table 1 shows the
proportions of each component, the pH, and the size of the oily droplets of
the emulsions as measured on a Coulter LS 130 laser sizing instrument
equipped with a circulating water bath.
TABLE 1
______________________________________
Chemical Mean
Percentage Mean
of Each pH of Coulter Coulter
Emulsion Size in Range in
Component Components Microns Microns
______________________________________
Triton X-100 2% 5.16 1.074 0.758-1.428
Tributylphosphate 2%
Soybean oil 16%
Water for injection 80%
(BCT-100)
Triton X-100 0.20% 5.37 0.944 0.625-1.333
Tributyl phosphate 0.20%
Soybean oil 1.60%
Water for injection 98%
(BCT-100 0.1).dagger.
Tween 20 2% 4.14 1.024 0.679-1.409
Tributyl phosphate 2%
Soybean oil 16%
Water for injection 80%
Tween 80 2% 6.04 1.030 0.706-1.380
Tributyl phosphate 2%
Soybean oil 16%
Water for injection 80%
______________________________________
.dagger.The BCT100 0.1 emulsion was obtained by diluting the BCT100
emulsion with water in a ratio of 1:9.
The emulsions of the present invention are highly stable. The BCT-100 and
BCT-100 0.1 emulsions have been found to be substantially unchanged after
storage at room temperature for at least seven months.
TABLE 7
______________________________________
Reduction in TCID-50 after
Virus 14 day Incubation
______________________________________
HSV-1 10.sup.5
HSV-2 10.sup.5.5
CMV 10.sup.6
VSV .sup. 10.sup.6.75
Adenovirus 5 0
______________________________________
The results shown above demonstrate that the BCT-100 emulsion and the
BCT-100 0.1 emulsion are both highly effective at inactivating a variety of
envelope viruses, even at the very high virus titers used in these
experiments. In contrast, the BCT-100 0.1 emulsion was not effective at
inactivating adenovirus, a non-envelope virus. The two emulsions show
approximately equal activity under the test conditions, despite the 10-fold
difference in concentration of trialkyl phosphate.
Tributyl phosphate alone is known to be toxic and irritating to mucous
membranes. However, when incorporated into the emulsions of the present
invention, these characteristics are not in evidence. As described below and
shown in FIG. 1, the emulsions are surprisingly non-toxic in animals.
The BCT-100 0.1 emulsion was tested for toxicity when orally administered to
rats. The emulsion was administered to Sprague-Dawley rats as a three
milliliter dose by gavage on day 0. The rats were weighed on days 0, 7 and
14. As can be seen from FIG. 1, all test animals survive and gain weight
after administration of the viricidal emulsion. Therefore, it is apparent
that the emulsion has no measurable oral toxicity, and actually appears
beneficial to the animals.
The BCT- 100 0.1 emulsion was also tested for dermal toxicity in rabbits
according to the protocols provided in 16 CFR .sctn.1500.3 (data not shown).
The BCT-100 0.1 emulsion was not irritating to skin in the animals tested.
The contents of all references cited throughout this application are hereby
incorporated by reference.
Those skilled in the art will recognize, or be able to ascertain using no
more than routine experimentation, many equivalents to the specific
embodiments of the invention described herein. Such equivalents are intended
to be encompassed by the following claims.
==============================================
So experimenters may experiment.
Regards
Ivan.
> -----Original Message-----
> From: Ivan Anderson [mailto:[email protected]]
> Sent: Thursday, 30 August 2001 14:28
> To: [email protected]
> Subject: RE: CS>POSSIBLE ANTHRAX CONTROL
>
>
> Thanks Brooks,
>
> Listers might be interested in a few posts upon this topic as discussed
> earlier this year which are quite detailed.
>
>
> http://escribe.com/health/thesilverlist/m31877.html
> http://escribe.com/health/thesilverlist/m32197.html
> http://escribe.com/health/thesilverlist/m32197.html
> http://escribe.com/health/thesilverlist/m32200.html
> http://escribe.com/health/thesilverlist/m32217.html
>
> Cheers
> Ivan.
>
>
> -----Original Message-----
> From: brooks bradley [mailto:[email protected]]
> Sent: Thursday, 30 August 2001 13:06
> To: [email protected]
> Subject: CS>POSSIBLE ANTHRAX CONTROL
>
>
>
>
> --
> The silver-list is a moderated forum for discussion of colloidal silver.
>
> To join or quit silver-list or silver-digest send an e-mail message to:
> [email protected] -or- [email protected]
> with the word subscribe or unsubscribe in the SUBJECT line.
>
> To post, address your message to: [email protected]
> Silver-list archive: http://escribe.com/health/thesilverlist/index.html
> List maintainer: Mike Devour <[email protected]>
>
>
